Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients

Class of 2017 Abstract === Objectives: To determine if the addition of oral alvimopan, liposomal bupivacaine and intravenous acetaminophen as part of a comprehensive enhanced recovery after surgery (ERAS) program decreases length of stay, recovery time and narcotic/acetaminophen use without affectin...

Full description

Bibliographic Details
Main Author: Weinstein, Sara
Other Authors: Bergstrom, Eric
Language:en_US
Published: The University of Arizona. 2017
Subjects:
Online Access:http://hdl.handle.net/10150/624256
http://arizona.openrepository.com/arizona/handle/10150/624256
id ndltd-arizona.edu-oai-arizona.openrepository.com-10150-624256
record_format oai_dc
spelling ndltd-arizona.edu-oai-arizona.openrepository.com-10150-6242562017-07-28T03:00:36Z Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients Weinstein, Sara Bergstrom, Eric College of Pharmacy, The University of Arizona Enhanced Recovery After Surgery (ERAS) Colorectal Surgery Class of 2017 Abstract Objectives: To determine if the addition of oral alvimopan, liposomal bupivacaine and intravenous acetaminophen as part of a comprehensive enhanced recovery after surgery (ERAS) program decreases length of stay, recovery time and narcotic/acetaminophen use without affecting colorectal surgery patient outcomes. Methods: Patients were compared before and after the implementation of alvimopan, liposomal bupivacaine and intravenous acetaminophen with an ERAS program. The primary outcome was hospital length of stay (measured in hours). Secondary outcomes included change in time to first meal, bowel sounds, and bowel movement (measured in hours), pain scores (visual analog scale 0-10), opioid use (measured in morphine equivalent milligrams), and acetaminophen use (measured in mg). Results: Thirty-seven individuals were included in the pre implementation population and fifty one patients were included in the post implementation population. The mean length of stay decreased from 124.3 hours to 100.2 hours (P equals 0.13) with the addition of the ERAS program with the three medications. The 24 hour morphine equivalent intervals for seventy-two hours following surgery decreased from 125.8 mg (day 1), 81.9 mg (day 2) and 44.5 mg (day 3) to 44.3 mg (day 1), 22.8 mg (day 2) and 13.2 mg (day 3) (P less than 0.005 for each one). Conclusions: The addition of alvimopan, liposomal bupivacaine and intravenous acetaminophen as part of a comprehensive ERAS program decreased length of stay but not significantly. However, the addition of these three medications with the ERAS program changes was associated with a statistically significant decrease in opioid use. 2017 text Electronic Report http://hdl.handle.net/10150/624256 http://arizona.openrepository.com/arizona/handle/10150/624256 en_US Copyright © is held by the author. The University of Arizona.
collection NDLTD
language en_US
sources NDLTD
topic Enhanced Recovery After Surgery (ERAS)
Colorectal Surgery
spellingShingle Enhanced Recovery After Surgery (ERAS)
Colorectal Surgery
Weinstein, Sara
Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients
description Class of 2017 Abstract === Objectives: To determine if the addition of oral alvimopan, liposomal bupivacaine and intravenous acetaminophen as part of a comprehensive enhanced recovery after surgery (ERAS) program decreases length of stay, recovery time and narcotic/acetaminophen use without affecting colorectal surgery patient outcomes. Methods: Patients were compared before and after the implementation of alvimopan, liposomal bupivacaine and intravenous acetaminophen with an ERAS program. The primary outcome was hospital length of stay (measured in hours). Secondary outcomes included change in time to first meal, bowel sounds, and bowel movement (measured in hours), pain scores (visual analog scale 0-10), opioid use (measured in morphine equivalent milligrams), and acetaminophen use (measured in mg). Results: Thirty-seven individuals were included in the pre implementation population and fifty one patients were included in the post implementation population. The mean length of stay decreased from 124.3 hours to 100.2 hours (P equals 0.13) with the addition of the ERAS program with the three medications. The 24 hour morphine equivalent intervals for seventy-two hours following surgery decreased from 125.8 mg (day 1), 81.9 mg (day 2) and 44.5 mg (day 3) to 44.3 mg (day 1), 22.8 mg (day 2) and 13.2 mg (day 3) (P less than 0.005 for each one). Conclusions: The addition of alvimopan, liposomal bupivacaine and intravenous acetaminophen as part of a comprehensive ERAS program decreased length of stay but not significantly. However, the addition of these three medications with the ERAS program changes was associated with a statistically significant decrease in opioid use.
author2 Bergstrom, Eric
author_facet Bergstrom, Eric
Weinstein, Sara
author Weinstein, Sara
author_sort Weinstein, Sara
title Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients
title_short Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients
title_full Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients
title_fullStr Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients
title_full_unstemmed Evaluating the Effects of Alvimopan, Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery Patients
title_sort evaluating the effects of alvimopan, liposomal bupivacaine and intravenous acetaminophen in colorectal surgery patients
publisher The University of Arizona.
publishDate 2017
url http://hdl.handle.net/10150/624256
http://arizona.openrepository.com/arizona/handle/10150/624256
work_keys_str_mv AT weinsteinsara evaluatingtheeffectsofalvimopanliposomalbupivacaineandintravenousacetaminophenincolorectalsurgerypatients
_version_ 1718507614247059456